SBIR-STTR Award

Bypassing fluidics in proteomic screening
Award last edited on: 11/21/05

Sponsored Program
SBIR
Awarding Agency
NIH : NIGMS
Total Award Amount
$504,000
Award Phase
2
Solicitation Topic Code
-----

Principal Investigator
Pascal Deschatelets

Company Information

Potentia Pharmaceuticals Inc

6400 Westwind Way Suite A
Crestwood, KY 40014
   (502) 241-4114
   pascal@potentiapharma.com
   www.apellis.com
Location: Single
Congr. District: 04
County: Oldham

Phase I

Contract Number: 1R43GM070193-01
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
2004
Phase I Amount
$252,000
The goal of this proposal is to develop a new, groundbreaking technology for the rapid identification of ligands for proteins. Every year, the pharmaceuticals industry loses about $3 billion by targeting genes/proteins wrongfully identified as the cause of disease. In the past decade, thousands of new genes/proteins with a potential role in disease have been identified. Simultaneously, millions of small molecule ligands have been generated in pharmaceutical libraries with little knowledge on their binding potential to these novel gene/protein targets. Potentia has developed a technology that will pave the way towards the matching of these ligands with new potential drug targets. Intelligent access to these libraries of ligands will generate a wealth of knowledge on disease mechanisms that is deemed to revolutionize the process of gene/protein validation in the drug industry. Potentia's technology is unique in its capacity to circumvent the inherent 'slowness' of analyzing molecules in solution. Proteins are immobilized on the tip of an atomic force microscope and then exposed to arrays of biosensors. Each biosensor is individually functionalized with a different small molecule ligand, resulting in Potentia's groundbreaking screening platform. The first aim of this proposal will be to eliminate background noise when functionalizing specialized biosensors with ligands in order to generate sensors for protein binding. The second aim will be to show that an atomic force microscope tip can be used as a bias electrode to gate our specialized biosensors. The third aim will be to determine whether it is possible to retrieve quantitative information from a binding event when using an atomic force microscope tip as a 'robotic arm' to bring a protein in contact with a ligand-coated biosensor. The success of this proposal will generate intelligence on millions of small molecule-protein interactions, generating unprecedented insight in the various gene/protein pathways and their role in disease

Phase II

Contract Number: 5R43GM070193-02
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
2005
Phase II Amount
$252,000
The goal of this proposal is to develop a new, groundbreaking technology for the rapid identification of ligands for proteins. Every year, the pharmaceuticals industry loses about $3 billion by targeting genes/proteins wrongfully identified as the cause of disease. In the past decade, thousands of new genes/proteins with a potential role in disease have been identified. Simultaneously, millions of small molecule ligands have been generated in pharmaceutical libraries with little knowledge on their binding potential to these novel gene/protein targets. Potentia has developed a technology that will pave the way towards the matching of these ligands with new potential drug targets. Intelligent access to these libraries of ligands will generate a wealth of knowledge on disease mechanisms that is deemed to revolutionize the process of gene/protein validation in the drug industry. Potentia's technology is unique in its capacity to circumvent the inherent 'slowness' of analyzing molecules in solution. Proteins are immobilized on the tip of an atomic force microscope and then exposed to arrays of biosensors. Each biosensor is individually functionalized with a different small molecule ligand, resulting in Potentia's groundbreaking screening platform. The first aim of this proposal will be to eliminate background noise when functionalizing specialized biosensors with ligands in order to generate sensors for protein binding. The second aim will be to show that an atomic force microscope tip can be used as a bias electrode to gate our specialized biosensors. The third aim will be to determine whether it is possible to retrieve quantitative information from a binding event when using an atomic force microscope tip as a 'robotic arm' to bring a protein in contact with a ligand-coated biosensor. The success of this proposal will generate intelligence on millions of small molecule-protein interactions, generating unprecedented insight in the various gene/protein pathways and their role in disease.

Thesaurus Terms:
biomedical equipment development, biosensor, chemical genetics, chemical structure function, intermolecular interaction, ligand, protein binding, proteomics, surface property chemical synthesis, high throughput technology, molecular biology information system, molecular film, polyethylene glycol, robotics, silane, surface coating atomic force microscopy, bioengineering /biomedical engineering, biotechnology, computer data analysis, electrical measurement